Resmetirom (Rezdiffra): Deep Dive into MAESTRO-NASH Data

Introduction

On March 14, 2024, Madrigal Pharmaceuticals' Thyroid Hormone Receptor beta (THR-β) agonist, Resmetirom (Brand name: Rezdiffra), received accelerated approval from the US FDA as the world's first treatment for MASH (Metabolic dysfunction-associated steatohepatitis, formerly NASH). (Note: Following the 2023 multi-society consensus, NAFLD/NASH nomenclature was updated to MASLD/MASH. This article uses "MASH" except when referring to historical trial names.)

This approval marks a monumental milestone, decisively ending the "winter era of MASH drug discovery," a period characterized by numerous high-profile late-stage pipeline failures. However, Resmetirom is not a "magic bullet" that completely cures all MASH patients. For all future MASH therapies in development, Resmetirom's clinical data has established the "absolute benchmark" that must be overcome.

This expanded article dissects the pivotal Phase 3 MAESTRO-NASH trial in detail (efficacy, baseline, safety), and adds subgroup analysis plus preclinical model translation.

1. MAESTRO-NASH Trial Overview and Baseline Characteristics

The MAESTRO-NASH trial was a 52-week, multi-center, double-blind, placebo-controlled Phase 3 study involving 966 adult patients with biopsy-confirmed MASH and moderate to advanced liver fibrosis (Stages F2 and F3)¹.

Baseline Patient Demographics

• Average Age: ~56 years
• Median BMI: ~35 (severe obesity)
• Type 2 Diabetes (T2D) Comorbidity: ~67% (majority of subjects)
• Fibrosis Stage Distribution: F3 ~62–65%, F2 ~30%, F1B minority
• Steatosis: moderate to severe in nearly all patients

Note: This heavily "F3-dominant" composition has significant implications for understanding the efficacy results.

2. Achievement of Co-primary Endpoints

The FDA set exceptionally high hurdles for MASH drug approval, requiring candidates to meet one or both of two co-primary endpoints. In the MAESTRO-NASH trial, Resmetirom successfully achieved both with resounding statistical significance.

Endpoint 1: NASH Resolution without worsening of fibrosis

Defined as an improvement in ballooning and inflammation (NAS score) with no worsening of the fibrosis stage.

Arm	Rate	p-value
Placebo	9.7%	—
Resmetirom 80mg	25.9%	<0.001
Resmetirom 100mg	29.9%	<0.001

👉 Deeper Dive into MoA: Resmetirom exhibits approximately 28-fold higher selectivity for THR-β over THR-α (functional assay EC50 ratio: THR-β 0.21 µM / THR-α 3.74 µM), purposefully avoiding cardiotoxicity and bone toxicity associated with THR-α activation³. Its exclusive hepatic targeting is driven by robust uptake via hepatocyte OATP transporters (OATP1B1/1B3) combined with high plasma protein binding. Intracellularly, it downregulates de novo lipogenesis (DNL), upregulates fatty acid β-oxidation, and increases CYP7A1-mediated bile acid synthesis (lowering LDL-C). This clears lipotoxicity rapidly, targeting the root of ballooning and steatosis.

Endpoint 2: Fibrosis improvement by ≥1 stage without worsening of NAS

Defined as the regression (reversal) of existing fibrosis by at least one stage, without any worsening of the NAFLD Activity Score.

Arm	Rate	p-value
Placebo	14.2%	—
Resmetirom 80mg	24.2%	<0.001
Resmetirom 100mg	25.9%	<0.001

👉 Analysis: Resmetirom showed a clear, statistically significant improvement in fibrosis compared to placebo. However, the sobering reality is that ~25% improvement means ~75% of patients' preexisting F2/F3 fibrosis did not improve. This limitation is exactly why the industry is now aggressively pursuing next-generation "direct liver anti-fibrotics."

3. Subgroup Analysis Insights

Integrated from FDA label, peer-reviewed publications, and AASLD/EASL presentations (100 mg arm, NASH Resolution, approximate values):

Subgroup	NASH Resolution (100 mg, approx)	Note
F2 patients	~35%	Better response than F3
F3 patients	~27%	Meaningful in established fibrosis
T2D comorbid	~28%	Similar to non-diabetic
Non-diabetic	~32%	Slightly higher response
BMI < 35	~32%	Stronger in milder obesity
BMI ≥ 35	~27%	Benefit also in severe obesity
Female	~33%	Trend toward higher response
Male	~27%	—

Note: Values are approximate, integrated from Harrison 2024 NEJM Forest plots, AASLD/EASL presentations, and the FDA label. Refer to primary sources for precise values.

Clinical implication: Resmetirom's weight-independent efficacy makes it a candidate to consider for the "Lean MASH" population where GLP-1RAs face sarcopenia concerns — this is an inference from the weight-independent mechanism rather than from Lean MASH–specific clinical evidence (see Semaglutide comparison).

4. Key Secondary Endpoints

Dramatic Hepatic Fat Reduction (MRI-PDFF)

Timepoint	80 mg	100 mg	Clinical significance
Week 16	-34.9%	-38.6%	Early response marker
Week 52	-28.8%	-33.9%	Durable effect

A ≥30% relative reduction in MRI-PDFF is highly regarded by the FDA and the industry as a robust surrogate marker for histological clinical efficacy in MASH—making this data definitive validation of Resmetirom's metabolic effect.

LDL-C and Cardiovascular Risk Reduction

Given CVD is the #1 cause of death in MASH patients, Resmetirom's 13–16% LDL-C reduction at Week 24 (regardless of statin use) suggests a favorable cardiovascular risk profile¹. ApoB and triglycerides also significantly reduced. Note that resmetirom-specific cardiovascular outcomes are still being verified in the ongoing MAESTRO-OUTCOMES trial and have not yet been definitively established.

Liver Enzymes

• ALT: up to -43% (100 mg, non-statin, Week 52 baseline)
• AST, GGT: similar significant reductions, corroborating subsiding of liver inflammation
• SHBG elevation: confirmed as on-target THR-β pharmacodynamic (PD) marker

5. Preclinical Model Translation

Resmetirom's preclinical efficacy is primarily established in the following.

5.1 GAN-DIO MASH Mouse Model

Kannt et al. 2021³ reported that GAN-DIO MASH mice treated with resmetirom (3 mg/kg/day, 8–12 weeks) showed:

• Steatosis score: ~50% reduction
• NAS: significant improvement
• Sirius red area: ~30% reduction
• Hydroxyproline content: ~25% reduction

Translation: Direction and magnitude align with clinical MAESTRO-NASH outcomes (~30% MASH resolution). Fat reduction dovetails with clinical MRI-PDFF data.

5.2 Performance Across MASH Models

Model	Steatosis	Inflammation	Fibrosis	Clinical translation
GAN-DIO	++	++	+	High
AMLN	++	+	+	Medium–High
CDAHFD (no obesity)	+	+	++	Medium (low metabolic axis)
CCl4-only	—	—	−	Inadequate (no metabolic axis)

See AMLN vs GAN comparison and MASH model selection guide.

6. Safety and Tolerability Profile

For any approved life-long medication, safety and tolerability are just as critical as efficacy.

Primary Adverse Events

Resmetirom was generally well-tolerated, but distinct gastrointestinal side effects were noted.

• Diarrhea: 28% in the 80 mg group, 33% in the 100 mg group (vs. 16% for placebo). Typically occurred during early weeks and tended to resolve over time.
• Nausea: ~22% in both treatment groups (vs. 13% for placebo).
• Discontinuation: 5–7% (slightly above placebo).

Notable Safety Advantages

• Weight-Independent Efficacy: Unlike GLP-1 agonists (e.g., Semaglutide) and FGF21 analogues, Resmetirom achieves MASH resolution and fibrosis reversal without inducing significant systemic weight loss. This distinguishes it as a direct metabolic liver modifier and opens applicability to Lean MASH and elderly patients.
• Thyroid Axis Changes: Transient and mild fluctuations in TSH and free T4 were noted; clinically significant drug-induced thyroid dysfunction was rare. Significant elevations in SHBG (Sex Hormone-Binding Globulin) confirm on-target THR-β activation.
• Low Risk of DILI: First-generation THR systemic toxicity (osteoporosis, cardiotoxicity, hepatotoxicity) via THR-α or poor targeting was successfully avoided.

7. Competitive THR-β Landscape

VK2809 (Viking Therapeutics, Ph2b VOYAGE), TERN-501 (Terns Pharmaceuticals, Ph2a DUET), and ASC41 (Ascletis, Ph2) are advancing as follow-on THR-β candidates. For the detailed competitive comparison (mechanism, selectivity, differentiation strategy), see the Post-Rezdiffra strategy article.

Resmetirom's first-mover advantage is substantial. For followers to displace it, they must clearly beat the MAESTRO-NASH numbers (~30% NASH resolution, ~25% fibrosis improvement) or differentiate via F4 expansion or combination therapy.

8. Future Challenges and FDA Label Limits

The success of the MAESTRO-NASH trial is a testament to matching the "right target (THR-β)" with a "meticulously designed clinical trial protocol."

FDA Label Scope

The FDA label (revised December 2025) strictly limits Rezdiffra's indication to adult patients with noncirrhotic MASH and moderate to advanced liver fibrosis (consistent with stages F2 to F3). It is explicitly not indicated for F4 (cirrhosis, compensated or decompensated), and the label separately states "Avoid use in patients with decompensated cirrhosis." On drug interactions, Resmetirom is a CYP2C8 substrate (coadministration with strong CYP2C8 inhibitors is contraindicated; moderate inhibitors require dose reduction) and an OATP1B1/1B3 inhibitor, which imposes dose caps (20–40 mg/day) on statins coadministered as OATP substrates.

Responder Prediction

Extensive use of non-invasive biomarkers (NITs: FIB-4, ELF, FibroScan, MRI-PDFF, Pro-C3) for patient screening will serve as a textbook model for future MASH trials (see also our comprehensive MASLD biomarker guide).

Combination Strategy

Single-agent limits are driving the combination therapy pipeline (Madrigal CSPC GLP-1, Sagimet FASN, GSK FGF21). Their readouts will define the future MASH market structure.

In preclinical MASH research, an industry benchmark is taking hold: "placing Resmetirom (or a closely related proxy) as a positive control and demonstrating candidate compound superiority through arm design" — a widely adopted comparator standard rather than a regulatory mandate.

References & Clinical Trials

1. Harrison SA, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis (MAESTRO-NASH). N Engl J Med. 2024;390(6):497-509. PubMed / NCT03900429

2. Harrison SA, et al. Resmetirom for nonalcoholic fatty liver disease (MAESTRO-NAFLD-1). Nat Med. 2023;29(11):2919-2928. PubMed

3. Kannt A, Wohlfart P, Madsen AN, Veidal SS, Feigh M, Schmoll D. Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis. Br J Pharmacol. 2021;178(12):2412-2423. PubMed

4. FDA. Rezdiffra (resmetirom) Prescribing Information. 2024.

Related Articles

• Post-Rezdiffra MASH Drug Discovery: Strategy and Preclinical Benchmarking
• The Frontline of Liver Anti-Fibrotic Drug Development 2026
• MASH Combination Therapy Pipelines 2026
• The Semaglutide Reality Check
• GLP-1 Agonists and Fibrosis: Beyond Semaglutide
• MASH Model Selection Guide
• AMLN vs GAN diet comparison
• Non-invasive biomarkers guide
• MASLD/MASH Biomarker Comprehensive Guide